![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Cempra Drug Stalled Over Wockhardt Manufacturing Concerns
Cempra Drug Stalled Over Wockhardt Manufacturing Concerns
![FDA_Logo_Black_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Black_2016.gif?t=1579040596&width=430)
November 9, 2016
The FDA is holding up approval of Cempra’s pneumonia drug Solithera (solithromycin) because of a ban of Wockhardt, its India-based API supplier.
Wockhardt has been sanctioned by the FDA twice this year. In June, Wockhardt received a Form 483 that cited nine cGMP violations, and in October the FDA banned all imports from a Wockhardt plant in India, putting it on the agency’s import alert list.
Cempra has stated that it is currently working with a new supplier to increase production in anticipation of a commercial launch.
Upcoming Events
-
21Oct